MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jnci/djag038

Медицинская библиотека · Journal of the National Cancer Institute · 2026

Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data.

Kawashiri Takehiro, Yamamoto Naru, Fujiwara Masaki, Shimizu Tadashi, Kobayashi Daisuke, Fujita Shunsuke, Shibata Nobuhito, Hirota Takeshi, Uchida Mayako

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Hematologic malignancies, including leukemias and lymphomas, remain life-threatening diseases for which preventive strategies have not yet been established. Recent studies have suggested that sodium-glucose cotransporter 2 (SGLT2) inhibitors have cancer-suppressive properties. This study investigated whether SGLT2 inhibitors are associated with reduced risk of hematologic malignancies in patients with diabetes, using a large-scale medical database.

METHODS

Data of patients with diabetes prescribed diabetes medications were extracted from the JMDC Payer database (January 2005 to November 2023). After exclusions, patients were categorized into SGLT2 inhibitor (n = 158 877) and non-SGLT2 inhibitor (n = 118 678) groups. Propensity score matching, accounting for patient characteristics, resulted in 102 478 matched patients per group. The primary endpoint was time to hematologic malignancy; secondary endpoints were time to lymphoma, leukemia, and their subcategories.

RESULTS

The incidence of hematologic malignancies was lower in the SGLT2 inhibitor group than in the non-SGLT2 inhibitor group (P < .001, hazard ratio [HR] = 0.73, 95% CI = 0.62 to 0.86, risk difference at 5 years (RD) = -0.16%). Lymphoma incidence was also lower in the SGLT2 inhibitor group (P = .003, HR = 0.71, 95% CI = 0.57 to 0.89, RD = -0.12%), whereas no clear evidence of difference was observed for leukemia (P = .06, HR = 0.76, 95% CI = 0.57 to 1.01, RD = -0.02%). Lymphocytic leukemia was associated with lower incidence compared to the non-SGLT2 inhibitor group (P = .04, HR = 0.44, 95% CI = 0.19 to 0.99, RD = -0.02%), whereas no clear evidence of difference was observed for myeloid leukemia (P = .12, HR = 0.76, 95% CI = 0.54 to 1.08, RD = -0.01%). Regarding acute myeloid leukemia (AML), the incidence was low in the SGLT2 inhibitor group (P = .001, HR = 0.34, 95% CI = 0.19 to 0.62, RD = -0.05%).

CONCLUSION

SGLT2 inhibitor use may be associated with lower risk of hematologic malignancies in adults with diabetes.

Для цитирования: Kawashiri Takehiro, Yamamoto Naru, Fujiwara Masaki, Shimizu Tadashi, Kobayashi Daisuke, Fujita Shunsuke, Shibata Nobuhito, Hirota Takeshi, Uchida Mayako. Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic malignancy risk: Insights from Japanese claims data.. Journal of the National Cancer Institute. 2026. DOI: 10.1093/jnci/djag038.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.